Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec and Active Biotech have entered into a medicinal chemistry collaboration under which Evotec will identify small molecule modulators of a biological target, selected by Active Biotech, involved in immune disorders and cancer.
Subscribe to our email newsletter
Evotec has established a position by assembling scientific experts and integrating technologies as well as experience and expertise in therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation.
Evotec COO Mario Polywka said their screening collaboration with Active Biotech has identified quality hits that they can now progress into a lead identification programme.
"We look forward to working with the team at Active Biotech in their quest to find novel treatments to address immune disorders and cancer," Polywka said.